47 related articles for article (PubMed ID: 38465434)
21. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives.
Dormann C
Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230
[TBL] [Abstract][Full Text] [Related]
22. The emergence of targeted therapy for HER2-low triple-negative breast cancer: a review of fam-trastuzumab deruxtecan.
Schreiber AR; O'Bryant CL; Kabos P; Diamond JR
Expert Rev Anticancer Ther; 2023; 23(10):1061-1069. PubMed ID: 37742278
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer.
Kotani D; Shitara K
Ther Adv Med Oncol; 2021; 13():1758835920986518. PubMed ID: 33473250
[TBL] [Abstract][Full Text] [Related]
24. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
Lee J; Park YH
Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
[TBL] [Abstract][Full Text] [Related]
25. Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines.
Simmons C; Rayson D; Joy AA; Henning JW; Lemieux J; McArthur H; Card PB; Dent R; Brezden-Masley C
Ther Adv Med Oncol; 2022; 14():17588359211066677. PubMed ID: 35035535
[TBL] [Abstract][Full Text] [Related]
26. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer: a plain language summary of the DESTINY-Gastric01 study.
Shitara K
Future Oncol; 2024 Jan; 20(2):59-70. PubMed ID: 37916503
[TBL] [Abstract][Full Text] [Related]
27. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
Indini A; Rijavec E; Grossi F
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
[TBL] [Abstract][Full Text] [Related]
28. Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for
Azar I; Alkassis S; Fukui J; Alsawah F; Fedak K; Al Hallak MN; Sukari A; Nagasaka M
Lung Cancer (Auckl); 2021; 12():103-114. PubMed ID: 34675733
[TBL] [Abstract][Full Text] [Related]
29. New treatment strategies for human epidermal growth factor receptor 2-positive breast cancer in 2023.
Banys-Paluchowski M; Krawczyk N; Stickeler E; Müller V; Fehm T
Curr Opin Obstet Gynecol; 2023 Feb; 35(1):54-61. PubMed ID: 36239554
[TBL] [Abstract][Full Text] [Related]
30. Systemic management of brain metastases in HER2+ breast cancer in 2022.
Alder L; Sammons S; Van Swearingen AED; Anders CK
Clin Adv Hematol Oncol; 2022 May; 20(5):325-336. PubMed ID: 35579591
[TBL] [Abstract][Full Text] [Related]
31. How we treat patients with metastatic HER2-positive breast cancer.
Nader-Marta G; Martins-Branco D; de Azambuja E
ESMO Open; 2022 Feb; 7(1):100343. PubMed ID: 34995893
[TBL] [Abstract][Full Text] [Related]
32. The Potential of Trastuzumab Deruxtecan as a Tissue Agnostic Drug.
Jørgensen JT
Oncology; 2023; 101(12):836-842. PubMed ID: 37651992
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic landscape of advanced HER2-positive breast cancer in 2022.
Gupta R; Gupta S; Antonios B; Ghimire B; Jindal V; Deol J; Gaikazian S; Huben M; Anderson J; Stender M; Jaiyesimi I
Med Oncol; 2022 Oct; 39(12):258. PubMed ID: 36224475
[TBL] [Abstract][Full Text] [Related]
34. Trastuzumab Deruxtecan: A Review in Unresectable or Metastatic HER2-Positive Breast Cancer.
Nie T; Blair HA
Target Oncol; 2023 May; 18(3):463-470. PubMed ID: 37129796
[TBL] [Abstract][Full Text] [Related]
35. The Future of HER2-Targeted Treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.
Nakano K
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069146
[TBL] [Abstract][Full Text] [Related]
36. Review of Survival, Safety, and Clinical Outcomes in HER2+ Metastatic Gastric Cancer Following the Administration of Trastuzumab.
Hackshaw MD; Bui CL; Ladner A; Tu N; Islam Z; Ritchey ME; Salas M
Cancer Treat Res Commun; 2020; 24():100189. PubMed ID: 32673845
[TBL] [Abstract][Full Text] [Related]
37. Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer.
Bartsch R
Expert Opin Investig Drugs; 2020 Sep; 29(9):901-910. PubMed ID: 32701032
[TBL] [Abstract][Full Text] [Related]
38. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
Adams E; Wildiers H; Neven P; Punie K
ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
[TBL] [Abstract][Full Text] [Related]
39. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
[TBL] [Abstract][Full Text] [Related]
40. A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer.
Nguyen X; Hooper M; Borlagdan JP; Palumbo A
Ann Pharmacother; 2021 Nov; 55(11):1410-1418. PubMed ID: 33629601
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
